Shareholder fury could see boardroom shake-up at GlaxoSmithKline

18 May 2003

Europe's leading drugmaker, GlaxoSmithKline, could replace several high-level executives, according to US and UK media reports, as the company moves to dilute shareholder discontent over revelations that chief executive Jean-Paul Garnier could leave with a $35 million "parachute payment."

The company, which has already been under fire from investors for its remuneration policy (Marketletters passim), maintains that its compensation packages merely reflect a broader increase in senior management pay packages as GSK brings its salary structure into line with US competitors like Pfizer and Merck & Co.

It was Mr Garnier's much-publicized proposed pay increase last year which first brought the matter to attention, although a package of around $30 million plus-benefits was ultimately shelved at the time in the face of widespread criticism.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight